This trial explanation is interesting. The study is complex, with two arms, first a safety arm followed by an efficacy arm. Only those patients with active metastatic TNC are included it looks like.

There is a near term secondary outcome measure - Overall survival rate at 1 year from start of therapy.

I wonder if the first patient has been dosed.